Shanghai Pharmaceuticals Holding Co., Ltd

SHSE:601607 Stock Report

Market Cap: CN¥59.4b

Shanghai Pharmaceuticals Holding Valuation

Is 601607 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 601607 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 601607 (CN¥17.92) is trading below our estimate of fair value (CN¥49.24)

Significantly Below Fair Value: 601607 is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for 601607?

Other financial metrics that can be useful for relative valuation.

601607 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue0.3x
Enterprise Value/EBITDA9.4x
PEG Ratio0.8x

Price to Earnings Ratio vs Peers

How does 601607's PE Ratio compare to its peers?

The above table shows the PE ratio for 601607 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average14.5x
000963 Huadong Medicine
19.6x15.6%CN¥57.6b
600998 Jointown Pharmaceutical Group
14.5x24.0%CN¥31.3b
600511 China National Medicines
12x10.5%CN¥26.2b
000028 China National Accord Medicines
12x8.8%CN¥18.0b
601607 Shanghai Pharmaceuticals Holding
17.5x20.7%CN¥59.4b

Price-To-Earnings vs Peers: 601607 is expensive based on its Price-To-Earnings Ratio (17.5x) compared to the peer average (14.5x).


Price to Earnings Ratio vs Industry

How does 601607's PE Ratio compare vs other companies in the CN Healthcare Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a25.3%
n/an/an/a
No. of CompaniesPE048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a25.3%
n/an/an/a
No more companies

Price-To-Earnings vs Industry: 601607 is good value based on its Price-To-Earnings Ratio (17.5x) compared to the CN Healthcare industry average (32.9x).


Price to Earnings Ratio vs Fair Ratio

What is 601607's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

601607 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio17.5x
Fair PE Ratio26.8x

Price-To-Earnings vs Fair Ratio: 601607 is good value based on its Price-To-Earnings Ratio (17.5x) compared to the estimated Fair Price-To-Earnings Ratio (26.8x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 601607 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCN¥17.92
CN¥20.78
+16.0%
18.2%CN¥26.40CN¥12.40n/a8
Apr ’25CN¥17.62
CN¥21.14
+20.0%
18.5%CN¥26.80CN¥12.40n/a8
Mar ’25CN¥18.21
CN¥21.60
+18.6%
17.6%CN¥26.80CN¥13.00n/a8
Feb ’25CN¥16.82
CN¥20.67
+22.9%
16.0%CN¥23.63CN¥13.00n/a8
Jan ’25CN¥16.73
CN¥21.17
+26.6%
10.5%CN¥23.63CN¥17.00n/a8
Dec ’24CN¥17.94
CN¥21.31
+18.8%
10.1%CN¥23.63CN¥17.00n/a8
Nov ’24CN¥18.05
CN¥21.31
+18.1%
10.1%CN¥23.63CN¥17.00n/a8
Oct ’24CN¥18.08
CN¥20.73
+14.6%
11.9%CN¥23.63CN¥17.00n/a8
Sep ’24CN¥17.84
CN¥23.51
+31.8%
19.0%CN¥29.21CN¥17.00n/a8
Aug ’24CN¥20.10
CN¥24.76
+23.2%
17.2%CN¥29.21CN¥17.00n/a10
Jul ’24CN¥22.41
CN¥24.31
+8.5%
17.1%CN¥29.21CN¥17.00n/a10
Jun ’24CN¥22.84
CN¥24.31
+6.4%
17.1%CN¥29.21CN¥17.00n/a10
May ’24CN¥22.91
CN¥24.31
+6.1%
17.1%CN¥29.21CN¥17.00CN¥17.9210
Apr ’24CN¥20.37
CN¥22.20
+9.0%
19.5%CN¥27.00CN¥14.51CN¥17.628
Mar ’24CN¥19.76
CN¥22.20
+12.3%
19.5%CN¥27.00CN¥14.51CN¥18.218
Feb ’24CN¥19.05
CN¥22.20
+16.5%
19.5%CN¥27.00CN¥14.51CN¥16.828
Jan ’24CN¥17.83
CN¥21.03
+17.9%
18.8%CN¥25.20CN¥14.51CN¥16.737
Dec ’23CN¥19.20
CN¥21.03
+9.5%
18.8%CN¥25.20CN¥14.51CN¥17.947
Nov ’23CN¥17.90
CN¥20.95
+17.0%
19.1%CN¥25.20CN¥14.51CN¥18.057
Oct ’23CN¥16.51
CN¥21.14
+28.1%
17.0%CN¥25.20CN¥16.06CN¥18.087
Sep ’23CN¥17.50
CN¥21.14
+20.8%
17.0%CN¥25.20CN¥16.06CN¥17.847
Aug ’23CN¥17.08
CN¥21.14
+23.8%
17.1%CN¥25.20CN¥16.06CN¥20.107
Jul ’23CN¥17.99
CN¥21.14
+17.5%
17.1%CN¥25.20CN¥16.06CN¥22.417
Jun ’23CN¥17.71
CN¥21.31
+20.3%
15.9%CN¥25.20CN¥16.06CN¥22.848
May ’23CN¥17.59
CN¥21.90
+24.5%
16.7%CN¥27.50CN¥16.06CN¥22.918

Analyst Forecast: Target price is less than 20% higher than the current share price.


Discover undervalued companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.